The German Institute for Quality and Efficiency in Health Care (IQWiG) has investigated whether patients suffering from non-Hodgkin lymphoma have (better) chances of recovery when stem cells from another person are transplanted. In its final report now presented, the Institute concludes that it is not possible to make statements on the benefit of this high-risk treatment. Meaningful studies are lacking for the often very small patient groups. For some questions, the data gap could be closed with the help of disease-specific registries.
* This article was originally published here
